- Home
- PGY vs PRAX Comparison
PGY vs PRAX Comparison
Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- PRAX
- Stock Information
- Founded
- PGY 2016
- PRAX 2015
- Country
- PGY United States
- PRAX United States
- Employees
- PGY N/A
- PRAX N/A
- Industry
- PGY Finance: Consumer Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- PRAX Health Care
- Exchange
- PGY Nasdaq
- PRAX Nasdaq
- Market Cap
- PGY 1.1B
- PRAX 1.2B
- IPO Year
- PGY N/A
- PRAX 2020
- Fundamental
- Price
- PGY $8.81
- PRAX $71.76
- Analyst Decision
- PGY Strong Buy
- PRAX Strong Buy
- Analyst Count
- PGY 9
- PRAX 9
- Target Price
- PGY $22.11
- PRAX $146.33
- AVG Volume (30 Days)
- PGY 2.7M
- PRAX 317.5K
- Earning Date
- PGY 11-12-2024
- PRAX 11-06-2024
- Dividend Yield
- PGY N/A
- PRAX N/A
- EPS Growth
- PGY N/A
- PRAX N/A
- EPS
- PGY N/A
- PRAX N/A
- Revenue
- PGY $970,898,000.00
- PRAX $1,605,000.00
- Revenue This Year
- PGY $25.98
- PRAX N/A
- Revenue Next Year
- PGY $16.03
- PRAX N/A
- P/E Ratio
- PGY N/A
- PRAX N/A
- Revenue Growth
- PGY 23.38
- PRAX N/A
- 52 Week Low
- PGY $8.56
- PRAX $14.25
- 52 Week High
- PGY $20.51
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- PGY 39.75
- PRAX 48.78
- Support Level
- PGY $10.62
- PRAX $58.84
- Resistance Level
- PGY $17.20
- PRAX $86.93
- Average True Range (ATR)
- PGY 1.12
- PRAX 6.09
- MACD
- PGY -0.37
- PRAX -0.15
- Stochastic Oscillator
- PGY 1.76
- PRAX 46.00
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.